MENU
XPH
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

XPH stock forecast, quote, news & analysis

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
a Summary for XPH with price predictions
Nov 06, 2026

XPH's RSI Oscillator ascends from oversold territory

The RSI Indicator for XPH moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 20 similar instances when the indicator left oversold territory. In 19 of the 20 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on XPH as a result. In 77 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.

The Moving Average Convergence Divergence (MACD) for XPH just turned positive on October 20, 2026. Looking at past instances where XPH's MACD turned positive, the stock continued to rise in 39 of 48 cases over the following month. The odds of a continued upward trend are 81%.

Following a +2.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where XPH advanced for three days, in 268 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 54 of 63 cases where XPH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for XPH entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN).

Industry description

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI").

Market Cap

The average market capitalization across the State Street SPDR S&P Pharmaceuticals ETF (XPH) ETF is 67.09B. The market cap for tickers in the group ranges from 31.04M to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is EYPT at 31.04M.

High and low price notable news

The average weekly price growth across all stocks in the State Street SPDR S&P Pharmaceuticals ETF (XPH) ETF was -0%. For the same ETF, the average monthly price growth was 3%, and the average quarterly price growth was 10%. XERS experienced the highest price growth at 42%, while ARVN experienced the biggest fall at -18%.

Volume

The average weekly volume growth across all stocks in the State Street SPDR S&P Pharmaceuticals ETF (XPH) ETF was 14%. For the same stocks of the ETF, the average monthly volume growth was 42% and the average quarterly volume growth was -4%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 50
Price Growth Rating: 50
SMR Rating: 71
Profit Risk Rating: 69
Seasonality Score: 7 (-100 ... +100)
XPH's RSI Oscillator ascends from oversold territory